Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411107 | 0.96 | CNR1 (0.41) | CNR1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL6265418 | 0.96 | CNR1 (0.41) | CNR1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL6265419 | 0.96 | CNR1 (0.41) | CNR1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL3443966 | 0.88 | CACNA2D1 (0.40) | CNR1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL3446579 | 0.84 | CACNA2D1 (0.44) | CNR1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL6265646 | 0.79 | CACNA2D1 (0.44) | CACNA2D1CACNA1BCACNB1CACNA1COPRM1 | |
| SCHEMBL3443970 | 0.77 | CTSS (0.47) | CACNA2D1CACNA1BCACNB1CACNA1COPRM1 | |
| SCHEMBL5189804 | 0.77 | CACNA2D1 (0.45) | CACNA2D1CACNA1BCACNB1CACNA1COPRM1 | |
| SCHEMBL3444305 | 0.76 | CACNA2D1 (0.44) | CACNA2D1CACNA1BCACNB1CACNA1COPRM1 | |
| SCHEMBL6262825 | 0.76 | CACNA2D1 (0.44) | CACNA2D1CACNA1BCACNB1CACNA1COPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7132551-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | SEPRACOR, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | AQUILA BRIAN M (US) | 2004-04-22 | — | — | US | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | PNMT, TAAR1, OPRL1 | CNR1 51/4885CACNA2D1 2524/4885CACNA1B 1631/4885 |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | CNR1 78/4885CACNA2D1 3322/4885CACNA1B 2623/4885 |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | CNR1 78/4885CACNA2D1 3322/4885CACNA1B 2623/4885 |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | SLC6A2, OPRL1, SLC18A2 | CNR1 78/4885CACNA2D1 3322/4885CACNA1B 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.